List of Excipients in Branded Drug VIOKACE

« Back to Dashboard

VIOKACE Excipient Strategy and Commercial Opportunities

Last updated: August 21, 2026

VIOKACE is an immediate-release pancrelipase tablet used with a proton-pump inhibitor to treat exocrine pancreatic insufficiency caused by chronic pancreatitis or pancreatectomy. Its commercial position is defined by three formulation requirements: preservation of porcine pancreatic enzymes, protection from gastric degradation, and reliable enzyme release in the intestine.

The strongest excipient opportunities are in enzyme stabilization, enteric protection, tablet robustness, dose flexibility, and alternative delivery formats. Generic competition faces a higher technical burden than ordinary oral solid-dose products because FDA approval must establish enzyme activity, dissolution, stability, content uniformity, and therapeutic performance across lipase, protease, and amylase components.

What is VIOKACE and how does its formulation work?

VIOKACE contains pancrelipase, a porcine-derived mixture of lipase, protease, and amylase. It is supplied in two tablet strengths:

Product	Lipase activity	Other declared activities
VIOKACE 10,440	10,440 USP units per tablet	39,150 USP units protease; 39,150 USP units amylase
VIOKACE 20,880	20,880 USP units per tablet	78,300 USP units protease; 78,300 USP units amylase

Patients take VIOKACE with a proton-pump inhibitor because the product is not designed to provide the same acid-resistant protection as enteric-coated pancrelipase microspheres. The PPI raises gastric pH and reduces enzyme inactivation before the tablet contents reach the small intestine. [1]

VIOKACE is therefore a formulation-dependent product. Its effectiveness depends on the interaction among enzyme activity, tablet disintegration, gastric pH, intestinal release, meal timing, and patient adherence.

What excipients are used in VIOKACE?

The FDA-approved label identifies the inactive ingredients as:

• Colloidal silicon dioxide
• Crospovidone
• Magnesium stearate
• Microcrystalline cellulose
• Sodium lauryl sulfate
• Hypromellose
• Talc
• Titanium dioxide
• Triacetin

The formulation uses conventional direct-compression or wet-granulation tablet excipients for mechanical strength and disintegration, combined with a film-coating system. The label does not identify a novel excipient or a proprietary delivery polymer as the primary source of product differentiation. [1]

The commercial value lies in how those excipients are selected and controlled. Pancreatic enzymes are proteins that can lose activity through moisture, heat, oxidation, adsorption, and unfavorable processing conditions. Small changes in granulation, compression force, lubricant level, coating weight, or storage humidity can affect enzyme potency and dissolution.

What excipient functions are commercially important for VIOKACE?

Enzyme stabilization

Microcrystalline cellulose provides tablet bulk and compressibility. Crospovidone promotes rapid tablet breakup. Colloidal silicon dioxide improves powder flow and can reduce manufacturing variability. Magnesium stearate reduces punch and die adhesion, but excessive lubrication can slow wetting and disintegration.

Sodium lauryl sulfate can improve wetting of hydrophobic or protein-containing particles. Its concentration must be controlled because surfactant exposure can affect protein structure, dissolution behavior, and gastrointestinal tolerability.

The most commercially valuable formulation work is likely to involve:

• Low-moisture processing
• Oxygen and humidity control
• Reduced enzyme adsorption to manufacturing equipment
• Optimized lubricant concentration
• Protection against thermal deactivation
• Improved activity retention during shelf life
• More consistent activity across the three enzyme classes

Tablet disintegration and enzyme release

VIOKACE must disintegrate rapidly enough to disperse enzyme particles after gastric transit, while retaining adequate physical integrity through manufacturing, packaging, transportation, and handling.

Crospovidone is central to this balance. Excessive compression can reduce its effectiveness. Insufficient compression can create friable tablets, variable packaging performance, and dose loss. Commercial formulation work can focus on optimizing:

• Crospovidone grade and particle-size distribution
• Microcrystalline cellulose grade
• Tablet porosity
• Compression force
• Granule density
• Coating weight
• Disintegration time after exposure to simulated gastric and intestinal fluids

Film coating and swallowability

Hypromellose, talc, titanium dioxide, and triacetin form a conventional film-coating system. The coating supports tablet appearance, handling, and swallowability. It does not convert VIOKACE into an enteric-coated product equivalent to delayed-release pancrelipase capsules.

Potential excipient opportunities include:

• Lower-weight film coatings
• Improved opacity using reduced titanium dioxide systems
• Color-free or low-color coatings
• Coatings that reduce tablet adhesion during packaging
• Moisture-barrier coatings
• Improved coating uniformity for high-potency enzyme tablets

A coating that materially changes gastric protection could alter the product's performance and regulatory classification. A manufacturer would need to demonstrate that the modified product remains pharmaceutically equivalent and clinically appropriate.

What excipient patents protect VIOKACE?

The public FDA label identifies the composition but does not establish that each excipient combination is independently patent-protected. Conventional excipients such as microcrystalline cellulose, crospovidone, hypromellose, talc, titanium dioxide, triacetin, and magnesium stearate are generally available from multiple suppliers.

The main intellectual-property value is more likely to reside in:

• The specific combination of pancrelipase enzyme activities
• Tablet manufacturing controls
• Enzyme stabilization methods
• Activity-preserving storage conditions
• Dissolution and release profiles
• Pharmaceutical compositions for pancreatic insufficiency
• Methods requiring administration with acid suppression
• Manufacturing processes that maintain lipase, protease, and amylase potency

A freedom-to-operate review should separate composition claims from process claims. A generic developer can often use the same compendial excipients while avoiding a claimed manufacturing sequence or a narrow enzyme-stabilization limitation.

How strong is the VIOKACE patent estate?

VIOKACE's commercial protection is less dependent on a single excipient patent than on regulatory complexity and the difficulty of reproducing a biologically derived enzyme product. The drug is not a monoclonal antibody, so biosimilar rules do not apply. It is an enzyme replacement product regulated as a drug, with generic development generally proceeding through an abbreviated new drug application rather than the biosimilar pathway.

The practical barriers are:

1. Demonstrating comparable enzyme activity.
2. Matching release and dissolution behavior.
3. Controlling activity degradation.
4. Establishing batch-to-batch uniformity.
5. Managing porcine raw-material sourcing.
6. Producing reliable analytical methods for three enzyme classes.
7. Addressing the clinical role of concomitant PPI therapy.

The patent estate should therefore be assessed alongside formulation know-how, manufacturing controls, supplier qualification, and regulatory precedent.

When does VIOKACE lose exclusivity?

VIOKACE received FDA approval in 2010 under NDA 022303. Its statutory five-year new chemical entity exclusivity expired in 2015, subject to the specific regulatory treatment of the product's active ingredient and approval date. Any applicable orphan-drug, pediatric, or listed-patent protections must be checked against the current FDA Orange Book and regulatory exclusivity records. [1][2]

The relevant commercial question is not only the expiration of statutory exclusivity. It is whether an applicant can obtain approval for an equivalent pancrelipase tablet and successfully commercialize it at a price that supports the required enzyme manufacturing infrastructure.

Protection or barrier	Relevance to VIOKACE
New chemical entity exclusivity	Expired based on 2010 approval
Orange Book patents	Must be checked against the current listing
Method-of-use claims	May affect labeling and Paragraph IV strategy
Formulation claims	May cover release, stabilization, or tablet composition
Manufacturing know-how	Can remain commercially important after patent expiration
Orphan exclusivity	Depends on the approved indication and FDA designation record
Biosimilar pathway	Not applicable; VIOKACE is not a biologic reference product

What Paragraph IV challenges and generic entry risks exist?

A generic applicant could challenge listed patents through a Paragraph IV certification if relevant patents remain in the Orange Book. The applicant would need to establish that the proposed product does not infringe, or that the patent is invalid or unenforceable.

For VIOKACE, potential generic entry scenarios include:

Same-strength tablet competition

A direct generic could match the 10,440 and 20,880 lipase-unit tablets. This approach would minimize dosing changes for prescribers and patients but would require close control of all declared enzyme activities.

Alternative strength strategy

A competitor could seek additional strengths or a different tablet count per dose. This could create commercial differentiation but would increase the formulation and regulatory burden.

Capsule or microsphere substitution

A capsule containing enteric-coated pancrelipase particles could compete clinically, but it would not be a simple generic substitute for VIOKACE. The product would likely follow a different formulation and labeling pathway, with distinct dissolution and dosing characteristics.

Authorized generic

The brand owner could launch an authorized generic through a licensing or supply arrangement. That strategy could reduce share loss while preserving manufacturing scale and improving payer access.

What formulation opportunities exist around VIOKACE?

Moisture-protective packaging

High-barrier blister packaging, desiccant systems, and improved bottle closures could extend enzyme stability and reduce potency loss after opening. Packaging changes may be commercially attractive because they can improve real-world storage performance without changing the active formulation.

PPI-free or acid-resistant formulations

The clearest product opportunity is a pancrelipase formulation that does not require a separate PPI. A true enteric-protected tablet, capsule, mini-tablet, or multiparticulate system could improve convenience and reduce acid-suppression exposure.

That product would compete more directly with delayed-release pancrelipase products such as CREON, ZENPEP, and Pertzye. The technical challenge is protecting enzyme activity in the stomach while providing predictable release in the duodenum.

Sprinkle and pediatric formats

Pancreatic enzyme replacement is used in children and patients who have difficulty swallowing tablets. Commercial opportunities include:

• Smaller enteric-coated beads
• Sachets for sprinkling on acidic soft foods
• Orally dispersible dosage forms
• Low-dose titration formats
• Unit-dose packaging
• Feeding-tube-compatible formulations

The excipient system would need to protect enzyme activity while avoiding unacceptable taste, agglomeration, moisture uptake, or tube obstruction.

Reduced-pill-burden products

Patients with pancreatic insufficiency may require multiple tablets or capsules with meals and snacks. High-potency products, combination strengths, and better dose flexibility could improve adherence. The commercial value depends on maintaining accurate enzyme-unit labeling and consistent activity through shelf life.

How does VIOKACE compare with competing pancrelipase products?

Product	Dosage form	Acid protection	PPI required by label	Main formulation opportunity
VIOKACE	Immediate-release tablet	Limited; used with PPI	Yes	PPI-free or improved stabilization
CREON	Delayed-release capsule with enteric-coated microspheres	Yes	No routine PPI requirement	Smaller particles, dose flexibility
ZENPEP	Delayed-release capsule with enteric-coated beads	Yes	No routine PPI requirement	Pediatric and sprinkle delivery
Pertzye	Delayed-release capsule with enteric-coated microspheres	Yes	No routine PPI requirement	Release control and tolerability
Pancreaze	Delayed-release capsule	Yes	No routine PPI requirement	Manufacturing efficiency and access

VIOKACE has a simpler solid tablet format but a less convenient administration requirement. Enteric-coated competitors have greater multiparticulate manufacturing complexity but offer stronger gastric protection.

For a generic developer, VIOKACE may appear technically simpler than a multiparticulate product. That advantage is limited by the need to reproduce enzyme activity and stability while satisfying tablet-specific quality attributes.

What commercial opportunities exist for excipient suppliers?

Excipient suppliers can target five areas:

1. Low-moisture tablet platforms. Grades of microcrystalline cellulose and crospovidone optimized for protein or enzyme products.
2. Protein-compatible lubricants. Magnesium-stearate alternatives or controlled lubrication systems that preserve disintegration.
3. Improved wetting systems. Surfactant or co-processed excipient systems that improve enzyme dispersion without compromising activity.
4. Moisture-barrier coatings. Hypromellose-based coatings with stronger humidity protection and low processing temperatures.
5. Multiparticulate delivery platforms. Enteric polymers, seal coatings, and fluid-bed systems for PPI-free pancrelipase products.

The strongest opportunity is not commodity supply. It is a qualified excipient platform supported by enzyme-compatibility data, stability packages, and scale-up experience.

What manufacturing and IP barriers affect VIOKACE competition?

Porcine pancreatic enzymes create supply and quality risks that conventional generic tablets do not face. Raw material variability can affect enzyme ratios, impurity profiles, activity, and batch release. Manufacturers must also manage animal-source documentation, viral and microbial controls, traceability, and consistency of extraction and purification.

Important manufacturing controls include:

• Enzyme activity assays for lipase, protease, and amylase
• Temperature and humidity control
• Low-shear blending
• Controlled lubricant addition
• Compression-force monitoring
• Coating uniformity
• Moisture-barrier packaging
• Stability testing under ICH conditions
• Supplier qualification for porcine enzyme material

These controls can create practical barriers even when composition patents have expired.

What is the FDA regulatory status of VIOKACE?

VIOKACE is FDA-approved under NDA 022303 for adults with exocrine pancreatic insufficiency due to chronic pancreatitis or pancreatectomy, administered with a PPI. The FDA label carries boxed-warning language concerning fibrosing colonopathy, a class risk associated with high-dose pancreatic enzyme replacement therapy. [1]

The product is a drug, not a biologic. Biosimilar approval is therefore not the relevant competitive pathway. Generic applicants would generally evaluate an ANDA strategy, subject to FDA requirements for pharmaceutical equivalence, bioequivalence where applicable, labeling, active-ingredient activity, and product-specific guidance.

Key Takeaways

• VIOKACE is an immediate-release pancrelipase tablet that requires coadministration with a PPI.
• Its listed excipients are conventional but must be optimized for enzyme stability, tablet disintegration, wetting, and moisture control.
• The strongest commercial opportunities are PPI-free acid-resistant delivery, pediatric sprinkle formats, high-barrier packaging, and reduced-pill-burden strengths.
• VIOKACE is not a biologic, so biosimilar competition is not the applicable framework.
• Generic entry depends on more than patent expiration. Enzyme sourcing, analytical testing, stability, and manufacturing consistency are significant barriers.
• A direct generic tablet would compete on price and access. A multiparticulate or enteric-protected product would compete on convenience and clinical performance.
• Excipient suppliers can create value through enzyme-compatible platforms rather than undifferentiated commodity materials.
• Current Orange Book listings and FDA exclusivity records should control any final Paragraph IV or launch analysis.

FAQs

Is VIOKACE enteric-coated?

No. VIOKACE is an immediate-release tablet used with a proton-pump inhibitor to reduce gastric acid exposure and preserve enzyme activity.

Can VIOKACE be reformulated without a proton-pump inhibitor?

Yes, in principle, but a PPI-free version would require a different acid-protection strategy, such as enteric-coated particles, mini-tablets, or a delayed-release dosage form.

Which excipient is most important for VIOKACE tablet disintegration?

Crospovidone is a key disintegrant, while microcrystalline cellulose, compression force, tablet porosity, and lubricant level also affect disintegration performance.

Does VIOKACE have biosimilar competition?

No. VIOKACE is a pancrelipase drug product rather than a biologic subject to the biosimilar pathway.

What is the largest commercial weakness of VIOKACE?

The requirement to administer VIOKACE with a PPI creates an adherence and convenience disadvantage compared with delayed-release pancrelipase products that provide enteric protection within the dosage form.

References

1. U.S. Food and Drug Administration. (2023). VIOKACE (pancrelipase) tablets, prescribing information. FDA.
2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
3. U.S. Food and Drug Administration. (2019). Draft guidance on pancrelipase delayed-release capsules and delayed-release tablets. FDA.
4. United States Pharmacopeia. (2024). USP-NF general chapters and monographs for pancreatic enzyme preparations. U.S. Pharmacopeial Convention.